We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Multicenter, Multi-national Open-label Program to Provide BMN 190 to Patients Diagnosed With CLN2 Disease

This treatment has been approved for sale to the public.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02963350
First Posted: November 15, 2016
Last Update Posted: July 24, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
BioMarin Pharmaceutical
  Purpose
  • To provide access to BMN 190 to patients with CLN2 disease who cannot participate in a clinical trial.
  • To collect additional information on the safety and tolerability of BMN 190 administration in patients with CLN2 disease.

Condition Intervention
CLN2 Disease Drug: BMN190, recombinant human tripeptidyl peptidase-1 (rhTPP1)

Study Type: Expanded Access     What is Expanded Access?
Official Title: A Multicenter, Multi-national Open-label Program to Provide BMN 190 to Patients Diagnosed With CLN2 Disease

Resource links provided by NLM:


Further study details as provided by BioMarin Pharmaceutical:

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   2 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Diagnosed with CLN2 disease as confirmed by deficient TPP1 enzyme activity in leukocytes or molecular analysis by identifying 2 known pathogenic mutations. If enzyme analysis is performed by dried blood spot, diagnosis must be confirmed with molecular testing
  • Age ≥2 old at the time of informed consent
  • Is willing and able to provide written, signed informed consent. Or, in the case of patients under the age of 18 (or other age as defined by regional law or regulation), provide written assent (if required) and have written informed consent, signed by a legally authorized representative, after the nature of the program has been explained, and prior to any program assessments.
  • If sexually active, must be willing to use 2 forms of acceptable methods of contraception while participating in the program.
  • If female of childbearing potential, must have a negative pregnancy test at Baseline and be willing to have additional pregnancy tests during the program.
  • Willing and able to comply with all program procedures.

Exclusion Criteria:

  • Another inherited neurologic disease, e.g., other forms of CLN or seizures unrelated to TPPI deficiency/CLN2 disease (patients with febrile seizures may be eligible).
  • Has received stem cell, gene therapy, or ERT for CLN2 disease.
  • Contraindications for neurosurgery (e.g., congenital heart disease, severe respiratory impairment, or clotting abnormalities).
  • Contraindications for MRI scans (e.g., cardiac pacemaker, metal fragment or chip in the eye, aneurysm clip in the brain).
  • Episode of generalized motor status epilepticus within 4 weeks before the first infusion.
  • Presence of ventricular abnormality (hydrocephalus, malformation).
  • Presence of ventricular shunt.
  • Has known hypersensitivity to any of the components of BMN 190.
  • Currently enrolled or previously enrolled in a clinical study with BMN 190.
  • Use of any investigational product or investigational medical device within 30 days prior to Baseline, or requirement for any investigational agent prior to completion of all scheduled program assessments.
  • Have travel plans that may interfere with dosing regimen, scheduled program visits and safety monitoring.
  • Has a medical condition or extenuating circumstance that, in the opinion of the physician, might compromise the patient's ability to comply with the protocol required testing or procedures or compromise the patient's wellbeing, safety, or clinical interpretability.
  • Pregnancy any time during the program; a female patient judged by the physician to be of childbearing potential will be tested for pregnancy.
  • A CLN2 combined motor/language score of less than 1 (apply to US only)
  • Asymptomatic (symptomatic is defined as having any evidence of neurological involvement attributed to CLN2 disease irrespective of the CLN2 score, including clinical signs and symptoms of disease such as seizures, ataxia, language delay or other developmental delays) (apply to US only)
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02963350


Locations
United States, California
Orange, California, United States
United States, Ohio
Columbus, Ohio, United States
Germany
Hamburg, Germany
Italy
Rome, Italy
United Kingdom
London, United Kingdom
Sponsors and Collaborators
BioMarin Pharmaceutical
Investigators
Study Director: Jessica Cohen Pfeffer, MD Medical Monitor
  More Information

Responsible Party: BioMarin Pharmaceutical
ClinicalTrials.gov Identifier: NCT02963350     History of Changes
Other Study ID Numbers: 190-502
First Submitted: November 9, 2016
First Posted: November 15, 2016
Last Update Posted: July 24, 2017
Last Verified: July 2017